K

EDBI logo

EDBI

Crunchbase
Pitchbook
Crunchbase

Deals on record

7

Common Fundraising Type

Series A

VFlowTech logo
VFlowTech

Energy storage • Vanadium redox flow batteries

Granite Asia logo
Wavemaker Partners logo
UntroD Capital logo
SEEDS Capital logo

VFlowTech develops and deploys vanadium redox flow batteries for long-duration energy storage solutions, supported by an AI-driven cloud energy management platform.

Equity
$20.5M
05/19/2025
Article
Addepar logo
Addepar

Technology • Data Platform

WestCap logo
Vitruvian Partners logo
Valor Equity Partners logo
EDBI logo

Addepar provides a technology and data platform for investment professionals to manage and analyze financial assets.

Series G
$230M
05/13/2025
Article
Nuevocor logo
Nuevocor

Biotechnology • Cardiomyopathies

Kurma Partners logo
SEEDS Capital logo
Highlight Capital logo
EDBI logo

Nuevocor is a biotechnology company developing treatments for genetic cardiomyopathies using its proprietary mechanobiology platform.

Series B
$45M
05/06/2025
Article
Callio Therapeutics logo
Callio Therapeutics

Antibody-drug conjugates • Cancer therapy

Frazier Life Sciences logo
SEEDS Capital logo
Pureos Bioventures logo
Platanus logo

Callio Therapeutics develops multi-payload antibody-drug conjugates for cancer therapy.

Series A
$187M
03/04/2025
Article
Sunbird Bio logo
Sunbird Bio

Biotechnology • Blood-based diagnostics

Polaris Partners logo
S32 logo
Eli Lilly and Company logo
EDBI logo

Sunbird Bio develops a blood-based diagnostic platform for early and accurate detection of neurological disorders like Alzheimer’s and Parkinson’s disease.

Equity
$14M
10/16/2024
Article
Engine Biosciences logo
Engine Biosciences

Precision Oncology • Machine Learning

ClavystBio logo
Polaris Partners logo
SEEDS Capital logo
Invus logo

Engine Biosciences uses machine learning and high-throughput biology to develop precision oncology medicines, and with their recent funding, they plan to advance their biomarker and target discoveries toward the clinic through internal development, collaborations, and partnerships.

Series A
$27M
10/31/2023
Article
Automera logo
Automera

Biotechnology • Cancer Treatment

ClavystBio logo
Accelerator Life Science Partners logo
Xora Innovation logo
EDBI logo

Automera is a biotechnology company that develops autophagy-targeting chimera small molecules (AUTACs) for the treatment of cancer and other diseases, using quantum chemistry and AI-enabled drug discovery tools to generate novel therapeutic leads.

Series A
$16M
09/27/2023
Article